Sign In
Buy EYEN
$7.56
+0 (+0%)
At Close: Jan 16, 2026
Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?
02:20pm, Thursday, 22'nd Aug 2024
Eyenovia Inc EYEN stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro.
Eyenovia Announces Pricing of $5.14 Million Public Offering
09:29am, Wednesday, 21'st Aug 2024
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,85
Eyenovia, Inc. Announces Proposed Public Offering
05:09pm, Tuesday, 20'th Aug 2024
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sel
Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know
01:06pm, Thursday, 15'th Aug 2024
Eyenovia (EYEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript
11:07pm, Monday, 12'th Aug 2024
Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer Bren Kern - Chief Operating Offic
Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates
06:31pm, Monday, 12'th Aug 2024
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.16 per share a year ago.
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Monday, 12'th Aug 2024
Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th
07:00am, Thursday, 08'th Aug 2024
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
Product-candidate would incorporate new steroid with the Optejet® for the millions of dry eye patients who experience periodic flare-ups Product-candidate would incorporate new steroid with the Optej
TAIPEI , Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovi
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
08:00am, Tuesday, 30'th Jul 2024
The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease
07:00am, Tuesday, 23'rd Jul 2024
Collaboration to focus on the development of a formulation of Senju's SJP-0035 for use with Eyenovia's Optejet® dispensing technology, following consultation with FDA
Eyenovia Announces Pricing of $5M Registered Direct Offering
08:00am, Friday, 28'th Jun 2024
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a secur
Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying
06:00am, Thursday, 23'rd May 2024
Penny stocks with insider buying addresses a key lingering concern among speculators: do the folks that are selling me their business actually believe in their business? I'm telling you, there's nothi
All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy
01:01pm, Monday, 20'th May 2024
Eyenovia (EYEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
